Navigation Links
Taking aim at metastatic lung tumors
Date:6/14/2010

A new study uses a sophisticated genomic analysis to unravel some of the complex cellular signals that drive the deadly invasive spread of lung cancer. The research, published by Cell Press in the June issue of the journal Cancer Cell, identifies specific molecules involved in the often fatal metastasis of a common type of non-small cell lung cancer (NSCLC) and uses this information to design effective therapeutic strategies.

"Previous cancer genomics studies have established a number of oncogene and tumor suppressor pathways as important for the initiation and maintenance of NSCLC," explains senior study author, Dr. Kwok-Kin Wong from the Dana-Farber Cancer Institute in Boston. "However, the molecular alterations necessary for invasion and metastases of NSCLC are less well-defined. Because metastasis causes much of the morbidity and incurability of cancer, there is an urgent need to elucidate the events underlying this biological process.

Dr. Wong and colleagues had recently shown that the loss of the Lkb1 tumor suppressor gene in a significant population of lung tumors results in metastasis in mice. Although the Lkb1 gene has also been linked with about 30% of human lung cancers, the pathways responsible for the metastatic effects had not been identified. To gain insight into the signaling pathways that underlie Lkb1-deficient lung tumors, the research team performed a comprehensive analysis of the genomic and signaling protein signatures of primary and metastatic lung tumors.

Loss of Lkb1 in mouse and human lung cancer cells was associated with an increase in the activity of proteins that are known to modulate cell motility and adhesion. Importantly, combined pharmacological inhibition of these key regulatory proteins in Lkb1-deficient cells decreased cell migration and induced tumor regression.

"Our analyses of primary and metastatic Lkb1-deficient mouse lung tumors have shown that progression to metastatic lung cancer is associated with unique gene and protein signatures," concludes Dr. Wong. "Importantly, our findings indicate that despite the complex transcriptional and signaling changes that occur in the setting of Lkb1 loss and progression of NSCLC, these tumors may still be addicted to isolated oncogenic events that can be successfully therapeutically targeted."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Genetic differences may influence joint pain among women taking lifesaving breast cancer drugs
2. Robin Leedy & Associates Hires Digital Content Producer, Taking Social Media for Drugstore Brands Digital Capability to the Next Level
3. Taking the final step from the bench to the hospital or clinic bedside
4. A Womans Touch Encourages Financial Risk-Taking
5. Harmony Information Systems to Host Free Webcast: Learn How Vermont and Pennsylvania Are Taking Control of Medicaid Waivers Management
6. Taking Flu Drugs While Pregnant Appears to Be Safe: Study
7. Triple Heart Valve Replacement Saves Local Women's Life at Portneuf Medical Center: Woman Gets a Second Chance at Life After Taking Fen-Phen
8. Taking Care of Your 'Girls': A Fun and Open Forum for Young Women Hosted by Abington Memorial Hospital
9. Binge drinking doesnt affect next-day student test-taking
10. People with prediabetes not taking adequate precautions to avoid diabetes
11. Celebrate National Childrens Dental Health Month by Taking Care of Tiny Teeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
Breaking Medicine Technology: